Abstracts und Poster
2019
AACR- American Association for Cancer Research Annual Meeting 2019, Atlanta
In vitro evaluation of TCR efficacy and toxicity using 3D spheroid models; Maja Buerdek, Kathrin Mutze, Kai Pinkernell, Dolores J. Schendel. Medigene Immunotherapies GmbH, Martinsried, Germany
2018
ASH - American Society of Hematology Annual Meeting 2018, San Diego
Immune Monitoring of Vaccine Quality and Persistence of Specific T Cell Responses in Five AML Patients Receiving Extended Dendritic Cell Vaccination Under Compassionate Use; Iris Bigalke1, Judith Eckl, PhD2, Guri Solum, MSc1, Kirsti Hønnåshagen, Msc1, Lisbeth Skoge, MSc1, Yngvar Fløisand, MD, PhD3, Dag Josefsen, MD, PhD1, Stein Sæbøe-Larssen, PhD1, Christiane Geiger, PhD2, Dolores Schendel, PhD2 and Gunnar Kvalheim, MD, PhD1. 1Oslo University Hospital, Oslo, Norway; 2Medigene AG, Planegg-Martinsried, GermanyDepartment of Hematology, 3Oslo University Hospital, Oslo, Norway
AACR - American Association for Cancer Research Annual Meeting 2018, Chicago, USA
Generation of clinical grade autologous TLR 7,8-polarized fast dendritic cell vaccines for active immunotherapy of patients with AML; Iris Bigalke1, Lisbeth Johanne Skoge1, Kirsti Hønnåshagen1, Christiane Geiger2, Gunnar Kvalheim1, Dolores J. Schendel2. 1Oslo University Hospital, Oslo, Norway; 2Medigene AG, Planegg-Martinsried, Germany
2017
AACR - American Association for Cancer Research Annual Meeting 2017, Washington, D.C., USA
Isolation and characterization of a PRAME-specific TCR with high avidity, potent antitumor efficacy and a favorable preclinical safety profile; Manon Weis, Carina Wehner, Christian Ellinger, Susanne Wilde, Dolores J. Schendel. Medigene Immunotherapies GmbH, Planegg/Martinsried, Germany
WT1 and PRAME mRNA transfected TLR 7/8-polarized fast DC vaccines in AML patients mount specific immune responses and impact progression free survival; Iris Bigalke1, Guri Solum1, Dag Josefsen1, Yngvar Fløisand1, Kirsti Hønnåshagen1, Lisbeth Skoge1, Signe Spetalen1, Stein Sæbøe-Larssen1, Dolores J. Schendel2, Gunnar Kvalheim1. 1Oslo University Hospital, Oslo, Norway; 2Medigene Immunotherapies GmbH, Germany
2016
Neoantigen Summit 2016, Boston, USA
Targeting neoantigens by TCR therapy: Are we limited to treatment of tumors with highmutational loads and patients with pre-existing neoantigen-specific T cells? Dolores J. Schendel, CEO and CSO Medigene AG, Munich Germany
ACCR - American Association for Cancer Research 2016, New Orleans, LA, USA
Tryggestad A., Axcrona K., Bigalke I., Inderberg-Suso, E., Skorstad, G., Axcrona U., Aamdal S., Gaudernack G., Schendel D., Lilleby W., Dueland S. and Kvalheim G. 2016. Clinical results of a Phase I/II trial of adjuvant therapeutic vaccination in high risk resected prostate cancer patients using autologous dendritic cells loaded with mRNA from primary prostate cancer tissue, hTERT and survivin. AACR, New Orleans, USA
2015
ASH - American Society of Hematology Annual Meeting 2015, Orlando FL, USA
Bigalke I., Fløisand Y., Solum G., Hønnåshagen K., Lundby M., Anderson K., Sæbøe-Larssen S., Inderberg E., Eckl J., Schendel D., and Kvalheim G. 2015. AML Patients in Minimal Residual Disease Vaccinated with a Novel Generation of Fast Dendritic Cells Expressing WT-1 and PRAME Mount Specific Immune Responses That Relate to Clinical Outcome. ASH Orlando, USA.
Phacilitate Immunotherapy Forum 2015, Washington DC, USA
Schendel D. 2014. Tailoring immunotherapies for patients with different stages of prostate cancer. Phacilitate Conference Washington DC, USA.
2014
ASH - American Society of Hematology Annual Meeting 2014, San Francisco, USA
Bigalke I., Honnashagen K., Lundby M., Kasten J., Suso Inderberg E., Skoge L., Saboe-Larssen S., Schendel D., Kvalheim G. 2014. 2440 Vaccination with a New Generation of Fast Dendritic Cells Transfected with mRNA from hTERT, Survivin and Autologous Tumor Mount Strong Immune Responses and Prolong Survival. ASH San Francisco, USA.
SITC - Society for Immunotherapy of Cancer Annual Meeting 2014, National Harbor MD, USA
Schnorfeil F., Lichtenegger F., Geiger C., Köhnke T., Bücklein V., Altmann T., Wagner B., Henschler R., Bigalke I, Kvalheim G., Hiddemann W., Schendel D.J., Subklewe M. 2014. Next-generation dendritic cells for immunotherapy of acute myeloid leukemia. SITC National Harbor, USA.
SITC - Society for Immunotherapy of Cancer Annual Meeting 2014, National Harbor MD, USA
Wehner C., Ellinger C., Raffegerst S., Wilde S., Mosetter B., Weis M., Longinotti G., Sailer N., Schendel D.J., Milošević S. 2014. Generation of tumor antigen specific CD4+ and CD8+ T cells by simultaneous MHC-I and –II epitope presentation in vitro and in vivo. SITC National Harbor, USA.
PIVAC - Progress in Vaccination Against Cancer 2014, Rom
Tryggestad A., Axcrona K., Bigalke I.,MInderberg-Suso E., Skorstad G, Axcrona U.,Steinar A., Gaudernack G.,Lilleby W., Dueland S., Kvalheim G. 2014. A PhaseI/II trial of adjuvant therapeutic vaccination in resected prostate cancer patients using autologous dendritic cells loaded with mRNA from primary prostate cancer tissue,hTERT and survivin. PIVAC Rome, Italy.
PIVAC - Progress in Vaccination Against Cancer 2014, Rom
Rampp I., Eichenlaub S., Römer I., Pohla H., Bigalke I., Sæbøe-Larssen S., Krackhardt A., Schendel D.J. Geiger C. 2014. Evaluation of a new generation dendritic cell-based vaccine for treatment of patients with castration-resistant prostate cancer. PIVAC Rome, Italy.
1st Immunotherapy of Cancer Conference 2014, München
Lichtenegger F., Beck B., Geiger C., Bigalke I., Kvalheim G., Hiddemann W., Schendel D., Subklewe M. 2014. Dendritic cell vaccination for postremission therapy in AML. ITOC Munich, Germany.
CIMT - Cancer Immunotherapy Annual Meeting 2014, Mainz
Tryggestad A.M.A., Bigalke I., Skorstad G., Skoge L.J., Honnashagen T.K., Axcrona K., Lilleby W., Kvalheim G. 2014. Cancer vaccines with hTERT and Survivin mRNA transfected fast DCs – a simplified and effective cancer vaccine. CIMT Mainz, Germany.
CIMT - Cancer Immunotherapy Annual Meeting 2014, Mainz
Schnorfeil F.M., Lichtenegger F.S., Geiger C., Beck B., Koehnke T., Buecklein V., Altmann T., Wagner B., Henschler R., Bigalke I., Kvalheim G., Hiddemann W., Schendel D.J., Subklewe M. 2014. Next-generation dentritic cell vaccination as postremission therapy in AML. CIMT Mainz, Germany.
CIMT - Cancer Immunotherapy Annual Meeting 2014, Mainz
Rampp I.S., Eichenlaub S., Römer I., Pohla H., Bilgalke I., Saeboe-Larssen S., Schendel D.J., Geiger C. 2014. Development of a next generation dentritic cell-based immunotherapie for patients with castration-resistant prostate cancer. CIMT Mainz, Germany.
CIMT - Cancer Immunotherapy Annual Meeting 2014, Mainz
Lorenz F.K.M., Wilde S., Voigt K., Kieback E., Schendel D.J., Uckert W. 2014. Gene optimization can generate cryptic epitopes that induce T cell responses. CIMT Mainz, Germany.
CIMT - Cancer Immunotherapy Annual Meeting 2014, Mainz
Bigalke I.,Honnashagen K., Lundby M., Kasten J., Inderberg Suso E.-M., Skoge L., Saboe-Larssen S., Schendel D.J., Kvalheim G. 2014. First clinical experience with a new generation of fast DCs transfected with mRNA from hTERT, survivin and autologous tumor. CIMT Mainz, Germany.
BioM seminar series 2014: m4-personalized medicine, München
Dr. Geiger C. 2014. A dendritic cell-based immunotherapy for patients with castration-resistant prostate cancer (CRPC). BioM Munich, Germany.
BioM forum 2014: Development and approval of ATMPs, München
Dr. Geiger C. 2014. "Dendritische Zellvakzine zur Behandlung minimaler residualer Krebserkrankungen - Discovery und Präklinik" (A dendritic cell vaccine for treatment of patients with minimal residual disease – discovery and pre-clinical development). BioM Munich, Germany.
Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie e.V. Jahrestagung 2014, Hamburg
Kobold S., Steffen J., Chaloupka M., Grassmann S., Henkel J., Castoldi R., Yi Zeng, Chmiliewski M., Schmollinger J., Schnurr M., Rothenfußer S., Schendel D.J., Abken H., Sustmann C, Niederfellner G., Klein C., Bourquin C., Endres S. 2014. Bispecific T cell recruiting antibody enhances anti-tumor activity of adoptive T cell transfer. DGHO Hamburg, Germany.
European Society for Blood and Marrow Transplantation Annual Meeting 2014, Mailand
von Luettichau I., Salat C., Wawer A., Noessner E., Eckl J., Multhoff G., Thiel U., Issels R.D., Kolb H.J., Burdach S. 2014. Targeting the Graft-Versus-Tumor Effect of DLI by Regional Hyperthermia to the Tumor Compartment. EBMT Milan, Italy.
2013
CIMT - Cancer Immunotherapy Annual Meeting 2013, Mainz
Ellinger C., Wehner C., Wilde S., Schendel D.J., Milošević S. Mai 2013. MHC Class-II Expression Targeting (CrossTAg) for the Generation of Tumor-Antigen-Specific CD4+ T Lymphocytes. CIMT Mainz, Germany.
CIMT - Cancer Immunotherapy Annual Meeting 2013, Mainz
Wehner C., Ellinger C., Raffegerst S., Wilde S., Mosetter B., Schendel D.J., Milošević S., 2013. Isolation of antigen-specific CD8+ T lymphocytes and molecular characterization of antigenic epitopes. CIMT Mainz, Germany.
SITC - Society for Immunotherapy of Cancer Annual Meeting 2013, National Harbor MD (USA)
Ellinger C., Wehner C., Wilde S., Schendel D.J., Milošević S. 2013. Induction and isolation of tumor antigen-specific CD4+ T lymphocytes using sorting signal directed MHC class-II expression. SITC National Harbor MD, USA.
SITC - Society for Immunotherapy of Cancer Annual Meeting 2013, National Harbor MD (USA)
Wehner C., Ellinger C., Raffegerst S., Wilde S., Mosetter B., Schendel D.J., Milošević S. 2013. Isolation of antigen-specific CD8+ T lymphocytes in vitro and in vivo. SITC National Harbor MD, USA.
SITC - Society for Immunotherapy of Cancer Annual Meeting 2013, National Harbor MD (USA)
Geiger C., Beck B., Bigalke I., Lichtenegger F.S., Heemskerk M., Saboe-Larssen S., Kvalheim G., Schendel D.J., Subklewe M. 2013. A new generation of dendritic cells optimized for the use in active immunotherapy – preclinical evaluation without an animal model. SITC National Harbor MD, USA.
Helmholtz Alliance 2013, Asselheim
Marin V., Longinotti G., Wieczorek A., Willde S., Mosetter B., Raffegerst S., Eckl J., Ellinger C., Frankenberger B., Leisegang M., Uckert W., Spranger S., Uharek L., Schendel D. 2013. Setting up of a GMP-compliant method for the production of human TCR-transduced T cells for the clinical testing. Helmholtz Alliance Asselheim, Germany.
Helmholtz Alliance 2013, Asselheim
Marin V., Longinotti G. 2013. Status of GMP process develompment for TCR expression in lymphocytes. Helmholtz Alliance Asselheim, Germany.
Cellular Therapie International Symposium 2013, Erlangen
Wilde S., Mosetter B., Wehner C., Ellinger C., Milosevic S., Frankenberger B., Schendel D. 2013. Isolation of NY-ESO-1-specific T cell receptors restricted by non-HLA-A*02:01 allotypes for TCR gene therapy. Cellular Therapie International Symposium Erlangen, Germany.
Cellular Therapie International Symposium 2013, Erlangen
Geiger C., Beck B., Bigalke I., Lichtenegger F.S., Heemskerk M., Saboe-Larssen S., Kvalheim G., Schendel D.J., Subklewe M. 2013. A DC-based therapeutic vaccine for AML patients: preclinical evaluation of a new generation of DCs expressing the leukemia-associated antigens WT1 and PRAME. Cellular Therapie International Symposium Erlangen, Germany.
ASH - American Society of Hematology Annual Meeting 2013, New Orleans LA (USA)
Lichtenegger F.S., Beck B., Geiger C., Munker D., Schlueter M., Draenert R., Kvalheim G., Hiddemann W., Schendel D.J., Subklewe M. 2013. Improving Efficacy of Dendritic Cell Vaccination in AML: Optimization of the DC Generation Protocol and Maximization of T Cell Responses by Immune Checkpoint Blockade. ASH New Orleans LA, USA.
Keystone Symposia 2013, USA
Smith S., Sommermeyer D., Schmitt T., Schendel D.J., Bernhard H., Piepenbrink K., Baker B., Blankenstein T., Uckert W., Greenberg P., Kranz D. 2013. Engineering high-affinity human single-chain T cell receptors against cancer antigens. Keystone Symposia, USA.
Acute Leukemias XIV, International Symposium 2013, München
PD Dr. Subklewe M. 2013. Dendritic Cell Vaccination for Postremission Therapy in AML. Acute Leukemias XIV München, Germany.
European Society for Blood and Marrow Transplantation Annual Meeting 2013, London (UK)
Wieczorek A., Marin V., Raffegerst S., Wilde S., Mosetter B ., Spranger S., Frankenberger B., Leisegang M., Uckert W., Uharek L., Schendel D.J. 2013. HMMR-redirected adoptive T cell therapy for treatment of refractory acute myeloid leukemia in context of mismatched stem cell transplantation. EBMT London, UK.
2012
SFB TR 36 Annual Meeting 2012 Berlin
Wilde S., Sommermeyer D., Leisegang M., Frankenberger B., Mosetter B., Uckert W., Schendel D.J. 2012. Human antitumor CD8+ T cells producing Th1-polycytokines show superior antigen sensitivity and tumor recognition. SFB TR 36 Berlin, Germany.